Associations of Coexisting Metabolic Dysfunction‐Associated Steatotic Liver Disease and Sarcopenia‐Related Abnormalities With Adverse Clinical Outcomes Across Obesity States
MedComm · 2026-11 · 7 (11)
DOI: 10.1002/mco2.71111 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 29.10.2026. Verfasst von Hong Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology Stanford University Medical Center Palo Alto California USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is associated with adverse liver and non‐liver outcomes, but the impact of coexisting sarcopenia‐related abnormalities (e.g., low muscle strength [MS], muscle mass, and physical performance) remains unclear. In a prospective UK Biobank cohort ( n = 438,748), we evaluated their joint associations with incidence and risks of all‐cause mortality, cirrhosis, hepatocellular carcinoma (HCC), cardiovascular disease (CVD), chronic kidney disease (CKD), non‐liver cancers, and obesity‐related cancers across MASLD and sarcopenia‐related abnormality status. Over a median follow‐up of 13.8 years, 401 HCC, 1714 cirrhosis, 39,534 CVD, 19,637 CKD, 38,240 non‐liver cancers, 12,536 obesity‐related cancers, and 34,801 deaths occurred. A stepwise increase in both incidence and adjusted risk of liver and non‐liver outcomes was observed across MASLD and sarcopenia strata. Within the coexistence group, the obesity (vs. non‐obesity) subgroup generally had higher risks. For example, for cirrhosis, adjusted hazard ratios increased from 3.93 to 7.36 then 8.48 with MASLD alone, coexisting MASLD with low MS overall and coexisting MASLD, low MS and obesity, respectively. Similar findings were observed in external validation analyses using the 2011–2018 US National Health and Nutrition Examination Survey cohort. Together, these observations inform risk stratification strategy and management of MASLD to include sarcopenia assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology Stanford University Medical Center Palo Alto California USA.
- The Third Unit Department of Hepatology Beijing Youan Hospital Capital Medical University Beijing China.
- Division of Gastroenterology and Hepatology Veterans Affairs Palo Alto Healthcare System Palo Alto California USA.
- Department of Nutrition Harvard T.H. Chan School of Public Health Boston Massachusetts USA.
- Yale University School of Nursing Orange Connecticut USA.
- Department of Epidemiology Yale School of Public Health New Haven Connecticut USA.
Zitieren
APA
Fan, H., Mao, X., Yan, T., Barnett, S., Zhang, J., Cheung, R., Zhang, X., & Nguyen, M. H. (2026). Associations of Coexisting Metabolic Dysfunction‐Associated Steatotic Liver Disease and Sarcopenia‐Related Abnormalities With Adverse Clinical Outcomes Across Obesity States. MedComm, 7(11). https://doi.org/10.1002/mco2.71111
Vancouver
Fan H, Mao X, Yan T, Barnett S, Zhang J, Cheung R, et al. Associations of Coexisting Metabolic Dysfunction‐Associated Steatotic Liver Disease and Sarcopenia‐Related Abnormalities With Adverse Clinical Outcomes Across Obesity States. MedComm. 2026;7(11). doi:10.1002/mco2.71111
BibTeX
@article{Fan2026,
author = {Fan, Hong and Mao, Xianhua and Yan, Taotao and Barnett, Scott and Zhang, Jing and Cheung, Ramsey and Zhang, Xuehong and Nguyen, Mindie H},
title = {Associations of Coexisting Metabolic Dysfunction‐Associated Steatotic Liver Disease and Sarcopenia‐Related Abnormalities With Adverse Clinical Outcomes Across Obesity States},
journal = {MedComm},
year = {2026},
volume = {7},
number = {11},
doi = {10.1002/mco2.71111}
}
EUVIMED